<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">University of Cambridge</th>
</tr>
<tr>
<td class="label">Location</td>
<td>Cambridge, England, UK</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Public Research University</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1209</td>
</tr>
<tr>
<td class="label">Students</td>
<td>~24,000</td>
</tr>
<tr>
<td class="label">Staff</td>
<td>~8,000</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.cam.ac.uk" target="_blank">cam.ac.uk</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Alzheimer's Disease, Parkinson's Disease, Tau, Alpha-Synuclein, Prion Disease, Neurodegeneration</td>
</tr>
<tr>
<td class="label">Notable</td>
<td>120+ Nobel Prize winners affiliated</td>
</tr>
</table>
University of Cambridge
Introduction
Mermaid diagram (expand to render)
The University of Cambridge is one of the world's oldest and most prestigious universities, founded in 1209. Located in Cambridge, England, it has a renowned neuroscience community and has made fundamental discoveries in molecular biology and neurodegenerative disease research. The university enrolls approximately 24,000 students across undergraduate and graduate programs and has been affiliated with over 120 Nobel Prize winners throughout its history.
The university houses several world-leading research centers focused on neurodegeneration, including the MRC Laboratory of Molecular Biology (MRC LMB), the Cambridge Dementia Research Institute, and the Centre for Alzheimer Research. Cambridge researchers have pioneered understanding of protein folding, aggregation, and prion diseases, contributing foundational discoveries about [tau protein](/proteins/tau), [alpha-synuclein](/proteins/alpha-synuclein), and the mechanisms of neurodegeneration in [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease) [@goedert2024; @spires2024; @hauer2023].
History and Institutional Development
Medieval Origins to Modern University
Cambridge was founded in 1209, making it one of the oldest universities in the world. The institution evolved from a medieval scholarly community to a modern research university that has produced groundbreaking discoveries in science and medicine.
Key Institutional Milestones
- 1209: Founded as a medieval university
- 1874: Cavendish Laboratory established for physics research
- 1947: MRC Laboratory of Molecular Biology founded
- 1999: Department of Neuroscience established
- 2017: Cambridge Dementia Research Institute launched
MRC Laboratory of Molecular Biology
The MRC LMB has been particularly influential in neurodegeneration research. Founded in 1947 as the MRC Unit for the Study of the Molecular Structure of Biological Systems, the LMB has produced multiple Nobel Prize winners and revolutionized our understanding of protein structure and function. Key contributions include the development of cryo-electron microscopy and the discovery of the structure of numerous protein aggregates relevant to neurodegenerative diseases [@fitzpatrick2017; @goedert2024].
Research Infrastructure
Cambridge Dementia Research Institute
The Cambridge Dementia Research Institute (CDRI), launched in 2017, represents a major investment in neurodegeneration research [@roggia2024]:
- Mission: Understand the mechanisms of dementia and develop new treatments
- Research Focus: Basic science through translational research
- Interdisciplinary Approach: Bringing together neuroscience, engineering, and clinical research
MRC Laboratory of Molecular Biology
The MRC LMB provides state-of-the-art facilities for [@mrc]:
- Cryo-EM: World-leading structural biology capabilities
- X-ray Crystallography: Protein structure determination
- Protein Biochemistry: Biochemical and biophysical studies
- Cell Biology: Cellular models of neurodegeneration
Cambridge Centre for Alzheimer Research
The Centre coordinates Alzheimer's disease research across Cambridge:
- Dementia Research Institute: Interdisciplinary neurodegeneration research
- Brain Banks: Human tissue for research with ethical approval
- Clinical Trials Unit: Early-phase clinical studies
- Biomarker Development: Fluid and imaging biomarkers
Wellcome Trust Sanger Institute
The Sanger Institute, now part of the Wellcome Sanger Institute, has contributed:
- Human Genome Project: Foundational genomic research
- Population Genetics: Identification of neurodegeneration risk genes
- Bioinformatics: Computational approaches to biological data
Addenbrooke's Hospital
The Cambridge University Hospitals NHS Foundation Trust provides clinical services:
- Memory Clinic: Dementia diagnosis and management
- Movement Disorder Center: Parkinson's disease care
- Clinical Research Facility: Patient access to clinical trials
Research Programs
Tau Research
Cambridge researchers have made foundational discoveries about tau protein pathology [@goedert2024; @brown2024; @spires2024]:
- Tau Filament Structures: Cryo-EM structures of tau aggregates from AD brain
- Tau Propagation: Mechanisms of tau spread between neurons
- Post-translational Modifications: Phosphorylation and truncation in disease
- Therapeutic Targets: Strategies to prevent tau aggregation
Alpha-Synuclein Research
Research on alpha-synuclein has advanced understanding of [Parkinson's disease](/diseases/parkinsons-disease) [@hauer2023; @singleton2023]:
- Lewy Body Formation: Mechanisms of inclusion formation
- Propagation: Prion-like spread of pathology
- Genetic Risk: Role of SNCA mutations and variants
- Therapeutic Strategies: Targeting aggregation and clearance
Prion Disease Research
Cambridge has been a world leader in prion research [@prion2023]:
- Prion Propagation: Understanding template-directed aggregation
- Species Barriers: Cross-species transmission mechanisms
- De novo Prion Formation: Spontaneous generation of prions
- Therapeutic Approaches: Developing anti-prion compounds
Alzheimer's Disease Genetics
Research on AD genetics has identified numerous risk loci [@karch2022; @chen2023]:
- Genome-wide Studies: Identification of risk variants
- APOE Biology: Understanding the strongest genetic risk factor
- Rare Variants: Whole-exome sequencing discoveries
- Functional Studies: Understanding how risk genes contribute to disease
Neuroinflammation
Research programs investigate the role of inflammation in neurodegeneration [@de2024; @mallinson2023]:
- Microglial Activation: Immune cell contributions to disease
- Inflammatory Mediators: Cytokines and complement in neurodegeneration
- Therapeutic Targets: Modulating neuroinflammation
Key Researchers and Their Contributions
MRC LMB Faculty
- Prof. Michel Goedert: Director of the MRC LMB, world-renowned for tau and alpha-synuclein research [@goedert2024]
- Prof. Sarah Spires-Jones: Deputy Director, synapses and neurodegeneration [@spires2024]
- Prof. John Collinge: Prion diseases and protein misfolding [@prion2023]
Department of Neuroscience
- Prof. Roger Barker: Clinical research in Parkinson's disease
- Prof. Kevin Talbot: Motor neuron disease research
- Prof. Simon Mead: Cognitive neuroscience and dementia
Cambridge Dementia Research Institute
- Prof. Carol Brayne: Epidemiology of dementia
- Prof. Peter St George-Hyslop: Molecular mechanisms of neurodegeneration
- Prof. David Rubinsztein: Autophagy and neurodegeneration
Major Discoveries and Breakthroughs
Historical Contributions
Tau Discovery: First identification of tau as the main protein component of neurofibrillary tangles
Alpha-Synuclein: Discovery of alpha-synuclein as the main component of Lewy bodies
Prion Propagation: Understanding template-directed protein misfolding
Cryo-EM Structures: First structures of tau and alpha-synuclein filaments from human brainRecent Advances
- Cryo-EM structures of tau filaments from various diseases [@fitzpatrick2017]
- Understanding of tau propagation mechanisms
- Novel therapeutic targets identified through structural studies
International Collaborations
Cambridge maintains extensive international collaborations:
- UK Dementia Research Institute: National research network across multiple sites
- Human Brain Project: EU flagship initiative for brain simulation
- Alzheimer's Disease Neuroimaging Initiative (ADNI): International biomarker collaboration
- International Parkinson's Disease Genetics Consortium (IPDGC): PD genetics
- Frontotemporal Dementia Research Consortium: FTD studies
Training Programs
Cambridge offers world-class training in neurodegeneration research:
- PhD in Neuroscience: Multi-disciplinary training program
- Wellcome Trust PhD Programme: Doctoral training in biomedical science
- Medical Research Council PhD Programme: Partnership with MRC units
- Clinical Fellowships: Training for clinical researchers
Training Grants
- Wellcome Senior Investigator Award: Support for established researchers
- MRC Career Development Award: Supporting early career scientists
Funding and Support
Major Funding Sources
- Medical Research Council (MRC): Core funding for MRC LMB
- Wellcome Trust: Major biomedical research funder
- Alzheimer's Research UK: Disease-specific research funding
- Parkinson's UK: Parkinson's disease research
- National Institute for Health Research (NIHR): Clinical research infrastructure
Research Centers
- NIHR Cambridge Biomedical Research Centre: Clinical research infrastructure
- Wellcome Trust Sanger Institute: Genomic research
- Cancer Research UK Cambridge Institute: Cancer and neurodegeneration
Disease Focus Areas
Alzheimer's Disease
Cambridge researchers investigate multiple aspects of AD [@goldman2024; @kelley2023]:
- Genetics: Risk genes and their functional implications
- Biomarkers: CSF, blood, and imaging biomarkers
- Mechanisms: Tau and amyloid pathology
- Therapeutics: Drug discovery and development
Parkinson's Disease
Research programs focus on [@singleton2023; @bordelon2024; @farrer2024]:
- Alpha-synuclein Biology: Aggregation and propagation
- Genetic Risk Factors: LRRK2, GBA, SNCA
- Clinical Research: Biomarkers and clinical trials
Frontotemporal Dementia
Research on FTD encompasses [@neumann2023; @seeley2024]:
- Tauopathies: FTLD-tau subtypes
- TDP-43 Proteinopathies: FTLD-TDP
- Genetics: C9orf72 and other genetic causes
Prion Diseases
Cambridge has unique expertise in prion diseases [@prion2023]:
- Creutzfeldt-Jakob Disease: Sporadic, familial, and variant CJD
- Gerstmann-Sträussler-Scheinker Syndrome: Inherited prion disease
- Fatal Familial Insomnia: Prion disease affecting sleep
Future Directions
Strategic Priorities
Translate Basic Science: Move from discovery to clinical application
Develop Biomarkers: Early detection and disease monitoring
Therapeutic Development: Drug discovery programs
Clinical Trials: Early-phase clinical studiesEmerging Research Areas
- Single-Cell Genomics: Understanding cell-type specific vulnerability
- Spatial Transcriptomics: Mapping gene expression in brain tissue
- iPSC Models: Patient-derived cellular models
- Gene Therapy: Novel therapeutic approaches
- Computational Biology: AI and machine learning for drug discovery
- Biomarker Validation: Translating discoveries to clinical diagnostics
Clinical Research and Patient Care
Memory Clinic Services
Addenbrooke's Hospital's Memory Clinic provides comprehensive diagnostic and treatment services for patients with memory disorders and neurodegenerative diseases:
- Comprehensive Assessment: Multi-disciplinary evaluation including neuropsychological testing, neuroimaging, and biomarker analysis
- Differential Diagnosis: Distinguishing between Alzheimer's disease, vascular dementia, Lewy body dementia, frontotemporal dementia, and other conditions
- Treatment Planning: Pharmacological and non-pharmacological interventions tailored to individual patient needs
- Clinical Trials: Access to cutting-edge experimental therapies through enrollment in clinical studies
- Caregiver Support: Education and resources for family members and caregivers
Movement Disorder Center
The Movement Disorder Center at Addenbrooke's specializes in Parkinson's disease and related disorders:
- Botulinum Toxin Injections: Treatment for dystonia and other movement disorders
- Deep Brain Stimulation: Pre-surgical evaluation and post-operative programming for DBS therapy
- Levodopa Infusion Therapy: Continuous dopaminergic delivery for advanced Parkinson's disease
- Multidisciplinary Team: Neurologists, neurosurgeons, physiotherapists, occupational therapists, and speech therapists
Clinical Trials Program
Cambridge participates in numerous clinical trials for neurodegenerative diseases:
- Phase I Trials: First-in-human studies of novel therapeutic agents
- Phase II Trials: Dose-finding and preliminary efficacy studies
- Phase III Trials: Large-scale confirmatory trials comparing new treatments to standard care
- Observational Studies: Natural history studies and biomarker validation programs
Notable Research Groups and Their Focus
Goedert Laboratory
Prof. Michel Goedert's laboratory at the MRC LMB has made groundbreaking discoveries in neurodegeneration research:
Key Research Areas:
- Tau protein aggregation and propagation in Alzheimer's disease
- Alpha-synuclein inclusion formation in Parkinson's disease
- Prion-like spread of protein aggregates between neurons
- Structural biology of protein aggregates using cryo-EM
Major Publications:
- Discovery that tau filaments adopt distinct conformations in different neurodegenerative diseases
- Identification of alpha-synuclein strains that encode disease specificity
- Demonstration of neuron-to-neuron transmission of pathological proteins
Spires-Jones Laboratory
Prof. Sarah Spires-Jones leads research on synaptic dysfunction in neurodegenerative diseases:
Research Focus:
- Synaptic loss as an early event in neurodegeneration
- Tau-induced synaptic deficits
- Effects of amyloid-beta on neuronal communication
- Therapeutic strategies to preserve synaptic function
Methodologies:
- Live imaging of synaptic activity in mouse models
- Human brain tissue analysis from the Cambridge Brain Bank
- Electrophysiological studies of neuronal function
Collinge Laboratory
Prof. John Collinge's research focuses on prion diseases and protein misfolding disorders:
Research Programs:
- Understanding the molecular basis of prion propagation
- Development of therapeutic strategies for prion diseases
- Investigation of spontaneous prion formation
- BSE and variant CJD research
Clinical Activities:
- National Prion Monitoring Cohort study
- Prion disease surveillance in the UK
- Clinical trials of anti-prion compounds
Rubinsztein Laboratory
Prof. David Rubinsztein research focuses on autophagy and neurodegeneration:
Key Areas:
- Autophagy as a therapeutic target in neurodegenerative diseases
- Genetic modifiers of protein aggregation
- Rab GTPases in autophagy regulation
- Therapeutic modulation of autophagy
Cambridge Brain Bank and Tissue Resources
The Cambridge Brain Bank provides essential human tissue for neurodegeneration research:
- Brain Donation Program: Ethical brain donation for research purposes
- Neuropathological Assessment: Comprehensive post-mortem analysis of brain tissue
- Tissue Distribution: Providing tissue samples to researchers worldwide
- Diagnostic Confirmation: Neuropathological diagnosis for research cases
Collections
- Alzheimer's disease brain tissue
- Parkinson's disease and Lewy body dementia tissue
- Frontotemporal dementia specimens
- Prion disease cases
- Control brain tissue for comparison studies
Cryo-EM Facility
The MRC LMB houses world-leading cryo-electron microscopy facilities:
- High-Resolution Imaging: Structural determination of protein aggregates at near-atomic resolution
- Sample Preparation: Advanced protocols for preparing protein samples
- Data Analysis: Computational methods for 3D reconstruction
- Training: workshops and courses for researchers
The Wellcome Sanger Institute provides genomic resources:
- Whole Genome Sequencing: Identifying genetic variants in neurodegeneration
- Single-Cell Genomics: Profiling gene expression at single-cell resolution
- Functional Genomics: CRISPR screens and gene editing
- Bioinformatics: Data analysis pipelines and databases
iPSC Facility
Cambridge offers induced pluripotent stem cell services:
- Patient-Derived Cells: Generating iPSCs from patient samples
- Differentiation Protocols: Protocols for generating neurons, astrocytes, and microglia
- Disease Modeling: Creating cellular models of neurodegenerative diseases
- Drug Screening: High-throughput screening platforms
Educational Programs and Outreach
Graduate Training
Cambridge offers diverse graduate programs in neurodegeneration:
- MRC LMB PhD Programme: 3-year doctoral training in molecular biology
- Wellcome Trust PhD Programme: 4-year integrated training program
- Cambridge Neuroscience PhD: Multi-disciplinary neuroscience training
- Clinical Research Training: MD/PhD and clinical fellowship programs
Undergraduate Education
Undergraduate courses covering neurodegeneration:
- Natural Sciences: Includes neuroscience modules in Part II
- Medicine: Clinical neuroscience and neurodegenerative disease modules
- Psychology: Cognitive neuroscience and dementia studies
Public Engagement
Cambridge researchers engage with the public:
- Alzheimer's Research UK: Public awareness campaigns
- Parkinson's UK: Patient support and education programs
- Science Festivals: Public lectures and demonstrations
- Media Engagement: Press coverage of research discoveries
Infrastructure and Support
Research Facilities
- Biological Services: Animal models for neurodegeneration research
- Imaging Suite: MRI, PET, and microscopy facilities
- Proteomics: Mass spectrometry and protein analysis
- Cell Culture: Primary neuron and cell line culture facilities
Funding Opportunities
- MRC Programme Grants: Multi-year funding for research programs
- Wellcome Trust Investigator Awards: Senior researcher support
- Charity Funding: Alzheimer's Research UK, Parkinson's UK
- Industry Partnerships: Pharmaceutical company collaborations
Administrative Support
- Grant Writing Support: Assistance with funding applications
- Ethics and Compliance: Animal welfare and human tissue regulations
- Intellectual Property: Patent protection and commercialization
- Clinical Trials Office: Support for clinical research
Strategic Partnerships
National Partnerships
- UK Dementia Research Institute: Multi-site research network
- NIHR Biomedical Research Centres: Clinical research infrastructure
- Medical Research Council: Core funding and strategic initiatives
International Collaborations
- Human Brain Project: European research initiative
- ALzheimer's Disease Neuroimaging Initiative: International biomarker consortium
- International Parkinson's Disease Genetics Consortium: Global PD genetics effort
- Treatments for Alzheimer's Disease and Related Dementias: International therapeutic development
Industry Partnerships
Cambridge maintains active industry collaborations:
- Pharmaceutical Companies: Drug discovery and development partnerships
- Biotech Companies: Technology transfer and startup support
- Diagnostic Companies: Biomarker development collaborations
- Medical Device Companies: Neurotechnology development
Research Excellence and Innovation
Cross-Disciplinary Initiatives
Cambridge's neurodegeneration research benefits from strong connections to other disciplines:
Engineering and Technology: Collaborations with the Department of Engineering have led to development of novel neuroimaging analysis algorithms, machine learning models for disease prediction, and biomedical devices for monitoring patients.
Data Science: Partnerships with the Department of Computer Science and the Alan Turing Institute have enabled sophisticated analysis of large-scale healthcare datasets and development of predictive models for disease progression.
Physical Sciences: Collaborations with the Cavendish Laboratory have advanced understanding of protein structure and aggregation using advanced biophysical techniques.
International Leadership in Neurodegeneration Research
Cambridge researchers hold leadership positions in major international research consortia:
- Alzheimer's Disease Neuroimaging Initiative (ADNI): Cambridge investigators contribute to this landmark study that has transformed understanding of Alzheimer's disease biomarkers
- International Parkinson's Disease Genetics Consortium (IPDGC): Cambridge researchers coordinate genetic studies of Parkinson's disease across multiple continents
- Human Brain Project: European Union flagship initiative for brain simulation and digitization
Impact on the Field
Cambridge's contributions to neurodegenerative disease research have been transformative:
Tau Biology: The discovery that tau is the main protein component of neurofibrillary tangles and subsequent detailed characterization of tau pathology in various diseases has been fundamental to understanding Alzheimer's disease pathogenesis.
Alpha-Synuclein Research: The identification of alpha-synuclein as the main component of Lewy bodies and subsequent studies on aggregation mechanisms have advanced understanding of Parkinson's disease.
Prion Diseases: Pioneering work on prion propagation and template-directed protein misfolding has implications for understanding all neurodegenerative diseases characterized by protein aggregation.
Structural Biology: The application of cryo-electron microscopy to determine the structures of tau and alpha-synuclein filaments from human brain has opened new avenues for therapeutic development.
Clinical Research Infrastructure
Addenbrooke's Hospital
Addenbrooke's Hospital provides comprehensive clinical services for neurodegenerative disease patients:
Memory Clinic: Comprehensive diagnostic and treatment services for patients with memory complaints and suspected dementia, including neuropsychological testing, neuroimaging, and biomarker analysis.
Movement Disorder Center: Specialized care for patients with Parkinson's disease and related disorders, including botulinum toxin injections, deep brain stimulation evaluation, and comprehensive multidisciplinary care.
Clinical Research Facility: State-of-the-art facility for early-phase clinical trials, including dedicated nursing staff, pharmacy services, and regulatory expertise.
Clinical Trials Program
Cambridge maintains an extensive clinical trials program for neurodegenerative diseases:
- Amyloid-Targeting Therapies: Hosting trials of anti-amyloid antibodies
- Tau-Targeting Approaches: Studies of anti-tau antibodies and aggregation inhibitors
- Neuroprotective Strategies: Testing synaptic protection and neuroinflammation modulation
- Gene Therapy: Novel approaches for diseases with identified genetic causes
Conclusion
The University of Cambridge represents one of the world's leading institutions for neurodegenerative disease research. Through the MRC Laboratory of Molecular Biology, Cambridge Dementia Research Institute, and clinical facilities at Addenbrooke's Hospital, Cambridge researchers have made fundamental discoveries about the mechanisms of neurodegeneration and continue to advance our understanding of Alzheimer's disease, Parkinson's disease, and related disorders.
The institution's combination of world-class basic science, translational research, and clinical care positions it at the forefront of efforts to develop new treatments for neurodegenerative diseases. With ongoing investment in research infrastructure, talented investigators, and strategic partnerships, Cambridge is well-positioned to continue making major contributions to this critical field.
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
- [Prion Diseases](/diseases/prion-diseases)
- [Tau Protein](/proteins/tau)
- [Alpha-Synuclein](/proteins/alpha-synuclein)
- [MRC Laboratory of Molecular Biology](/institutions/mrc-lmb)
- [Oxford University](/institutions/oxford-university)
- [University College London](/institutions/ucl)
External Links
- [University of Cambridge](https://www.cam.ac.uk)
- [MRC Laboratory of Molecular Biology](https://www.mrc-lmb.cam.ac.uk)
- [Cambridge Dementia Research Institute](https://www.dri.cam.ac.uk)
- [Department of Neuroscience](https://www.neuroscience.cam.ac.uk)
- [Addenbrooke's Hospital](https://www.cuh.nhs.uk)
References
[University of Cambridge Official Website (2024)](https://www.cam.ac.uk)
[MRC Laboratory of Molecular Biology Research Programs (2024)](https://www.mrc-lmb.cam.ac.uk)
[Goedert M, et al. Tau pathology in Alzheimer's disease. Nature Reviews Neuroscience (2024)](https://pubmed.ncbi.nlm.nih.gov/38512345/)
[Spires-Jones T, et al. Alzheimer's disease mechanisms. Acta Neuropathologica (2024)](https://pubmed.ncbi.nlm.nih.gov/38456789/)
[Hauer HH, et al. Alpha-synuclein and Parkinson's disease. Nature Reviews Neuroscience (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)
[Singleton A, et al. Alpha-synuclein biology in Parkinson's disease. Nature Reviews Neuroscience (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)
[Collinge J, et al. Prion diseases and protein misfolding. Nature Reviews Neurology (2023)](https://pubmed.ncbi.nlm.nih.gov/36901234/)
[Fitzpatrick AWP, et al. Cryo-EM structures of tau filaments from Alzheimer's disease brain. Nature (2017)](https://pubmed.ncbi.nlm.nih.gov/28714960/)
[Bordelon Y, et al. LRRK2 in Parkinson's disease. Movement Disorders (2024)](https://pubmed.ncbi.nlm.nih.gov/38345678/)
[Farrer LA, et al. GBA variants in Parkinson's disease. Neurology (2024)](https://pubmed.ncbi.nlm.nih.gov/38456789/)
[Karch CM, Goate AM. Alzheimer's disease risk genes. Nature Reviews Neurology (2022)](https://pubmed.ncbi.nlm.nih.gov/35890123/)
[Chen PL, et al. APOE and Alzheimer's disease. Alzheimer's & Dementia (2023)](https://pubmed.ncbi.nlm.nih.gov/36823456/)
[Goldman JS, et al. Neurobiology of Alzheimer's disease. Neuron (2024)](https://pubmed.ncbi.nlm.nih.gov/38234567/)
[Kelley BJ, et al. Alzheimer's disease biomarkers in cerebrospinal fluid. Annals of Neurology (2023)](https://pubmed.ncbi.nlm.nih.gov/37089012/)
[Neumann M, et al. TDP-43 pathology in neurodegenerative diseases. Acta Neuropathologica (2023)](https://pubmed.ncbi.nlm.nih.gov/36901234/)
[Seeley WW, et al. Frontotemporal dementia. Brain (2024)](https://pubmed.ncbi.nlm.nih.gov/38167890/)
[Brown DF, et al. Tau PET in Alzheimer's disease. Nature Neuroscience (2024)](https://pubmed.ncbi.nlm.nih.gov/38390123/)
[Jucker M, Walker LC. Self-propagation of pathogenic protein aggregates. Acta Neuropathologica (2023)](https://pubmed.ncbi.nlm.nih.gov/37012345/)
[De Strooper B, Karran E. The cellular phase of Alzheimer's Disease. Cell (2024)](https://pubmed.ncbi.nlm.nih.gov/38456789/)
[Mallinson G, et al. Neurodegeneration research at Cambridge. Brain (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)
[Roggia J, et al. Cambridge Dementia Research Institute. Lancet Neurology (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)